Iproclozide
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | N06AF06 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 3544-35-2 |
PubChem (CID) | 19063 |
ChemSpider | 17998 |
UNII | 1II9D6CB3J |
KEGG | D07338 |
ChEMBL | CHEMBL91238 |
ECHA InfoCard | 100.020.536 |
Chemical and physical data | |
Formula | C11H15ClN2O2 |
Molar mass | 242.70 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[1] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[2][3]
See also
References
- ↑ Suerinck A, Suerinck E (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.
- ↑ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction.". Gastroenterology. 75 (3): 492–496. PMID 680506.
- ↑ Neil Kaplowitz; Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.